Neurology Alert – October 1, 2006
October 1, 2006
View Issues
-
More Good News for Stroke Prevention — Statins and ACE Inhibitors Really Work!
Until now, neurologists have relied on large studies of patients with coronary atherosclerosis and hyperlipidemia who were treated with statins and were found, as a secondary outcome, to have a reduced risk of ischemic stroke. -
Genetic Risk Factors for Myopathies Induced by Lipid-Lowering Drugs
Patients with myopathies induced by lipid-lowering drugs, including statins and fibrates, have an increased rate of genetic muscle disorders. -
Cluster Headaches
Cluster headache may be accompanied by a variety of neurological manifestations, and responds well to triptans and oxygen therapy. -
Is Ginkgo Biloba Comparable to Donepezil for Treating AD?
Ginkgo biloba has been used by practitioners of Eastern medicine for centuries to boost memory and other health purposes. -
Impulse Control Disorders in Parkinson's Disease: Too Much of a Good Thing?
Treatment of Parkinson's disease with dopamine agonist medications may precipitate impulse-control disorders such as compulsive gambling, buying, and hypersexuality -
α-Synuclein Promoter Variability Affects Risk for Parkinson's Disease
α-synuclein mutations leading to Parkinson's disease are extremely rare. However, based upon this study, variability in the gene promoter may account for up to 3% of the risk of Parkinson's disease in the general population. -
Cardiac Surgery and Cerebrovascular Disease: What are the Risks, Options?
The neurological risk of cardiac surgery is still not well characterized, but post-operative strokes occur in 3-9% of patients. A decrease in intra-operative blood pressure and increased cardiopulmonary bypass time may result in watershed infarcts. -
Pharmacology Watch
A team from UCSF recently reviewed company documents that were entered into the public record as a result of litigation over the promotion of gabapentin (Neurontin) between 1994 and 1998. -
Clinical Briefs in Primary Care Supplement